June 2014—Enzo’s quantitative, high-sensitivity ELISA kit for Alzheimer research enables identification and quantification of APP ∆C31. It detects as little as 0.92 pM of APP ∆C31 in human cell lysate and cerebral spinal fluid samples and provides analysis of up to 38 duplicate samples in two hours. The ELISA displays high specificity to human APP ∆C31 with low cross-reactivity to other APP isoforms. The assay was developed with the Buck Institute for Research on Aging, which validated use of the assay in drug screening applications for caspase inducers and caspase inhibitors.
The 96-well break-apart precoated microtiter strip plate provides throughput flexibility to minimize waste, and the liquid reagents are color-coded.
Enzo Life Sciences, 800-942-0430